NCT07457372

Brief Summary

The purpose of this study is to determine the feasibility of using non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) to examine physiological and psychological responses in a college-aged healthy population

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable

Timeline
22mo left

Started Jul 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 3, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 9, 2026

Completed
4 months until next milestone

Study Start

First participant enrolled

July 1, 2026

Expected
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2028

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2028

Last Updated

May 20, 2026

Status Verified

May 1, 2026

Enrollment Period

1.8 years

First QC Date

March 3, 2026

Last Update Submit

May 18, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in plasma glucose

    Hour 2 after oral glucose load

Study Arms (2)

Active taVNS

ACTIVE COMPARATOR
Device: Active taVNS

Sham taVNS

PLACEBO COMPARATOR
Device: Sham taVNS

Interventions

Actual taVNS

Active taVNS

No nerve stimulation

Sham taVNS

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Participants must be between the ages of 18 and 35 as we are focused on recruiting undergraduate and graduate students.

You may not qualify if:

  • Participants will be excluded if they have epilepsy, clinically significant tachycardia or arrhythmia, diabetes (Type 1 or Type 2) or another metabolic disease, current pregnancy, any implanted electronic medical device (for example, pacemaker or defibrillator), or a known skin allergy to adhesives that would prevent CGM placement. Participants will also be excluded if they have a history of major depressive disorder if taVNS could reasonably be expected to alter mood symptoms

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Minnesota Duluth

Duluth, Minnesota, 55812, United States

Location

Study Officials

  • Mark Hartman, PhD

    University of Minnesota

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mark Hartman, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: This is a within-subject, counterbalanced repeated-measures study with two experimental conditions (active taVNS and sham taVNS)
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 3, 2026

First Posted

March 9, 2026

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

May 1, 2028

Study Completion (Estimated)

May 1, 2028

Last Updated

May 20, 2026

Record last verified: 2026-05

Locations